Ergomed plc Notice of Preliminary Results (0086A)
21 March 2017 - 6:02PM
UK Regulatory
TIDMERGO
RNS Number : 0086A
Ergomed plc
21 March 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Ergomed plc
Notice of Preliminary Results
London, UK - 21 March 2017: Ergomed plc (LSE: ERGO) ('Ergomed'
or 'the Company'), a company dedicated to the provision of
specialised services to the pharmaceutical industry and the
development of new drugs, will announce its unaudited preliminary
results for the year ended 31 December 2016 on Tuesday 28 March
2017.
A meeting for analysts will be held at 9:30am on 28 March 2017
at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London EC1A 4HD.
-ENDS -
Enquiries:
Ergomed plc Tel: +44 (0) 1483
503205
Miroslav Reljanovic (Chief
Executive Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
Stifel Nicolaus Europe Limited Tel: +44 (0) 20
7710 7600
Jonathan Senior (Joint Broker)
FTI Consulting - for UK enquiries Tel: +44 (0) 20
3727 1000
Simon Conway / Mo Noonan /
Natalie Garland-Collins
MC-Services - for Continental Tel: +49 211 52925222
European enquiries
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed recently acquired a pipeline of proprietary development
products for haemostasis in surgical settings. For further
information, visit: http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORJMMLTMBMTBLR
(END) Dow Jones Newswires
March 21, 2017 03:02 ET (07:02 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024